LP-10 (Liposomal Tacrolimus)
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oral Lichen Planus
Conditions
Oral Lichen Planus
Trial Timeline
Jul 1, 2024 → Jun 1, 2025
NCT ID
NCT06233591About LP-10 (Liposomal Tacrolimus)
LP-10 (Liposomal Tacrolimus) is a phase 2 stage product being developed by Lipella Pharmaceuticals for Oral Lichen Planus. The current trial status is active. This product is registered under clinical trial identifier NCT06233591. Target conditions include Oral Lichen Planus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06233591 | Phase 2 | Active |
Competing Products
20 competing products in Oral Lichen Planus